Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AnsellASX:ANN -1.02%74 Price-to-Tangible-Book is 12.17 as of Sep. 08, 2026. GuruFocus rates ASX:ANN with a GF Score™ of 74/100 and a GF Value™ of A$31.65 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 701 Medical Devices & Instruments companies, Ansell ranks worse than 89.02% on this metric.
As of today (2026-09-08), Ansell's share price is A$41.83. Ansell's Tangible Book per Share of Jun. 2026 for the quarter that ended in Jun. 2026 was A$3.44. Hence, Ansell's Price to Tangible Book Ratio of today is 12.17.
The historical rank and industry rank for Ansell's Price-to-Tangible-Book or its related term are showing as below:
ASX:ANN'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.05 Med: 8.38 Max: 16.41
Current: 12.17
During the past 13 years, Ansell's highest Price to Tangible Book Ratio was 16.41. The lowest was 3.05. And the median was 8.38.
ASX:ANN's Price-to-Tangible-Book is ranked worse than 89.02% of 701
companies
in the Medical Devices & Instruments industry
Industry Median: 2.62
vs ASX:ANN: 12.17
A closely related ratio is called PB Ratio. As of today, Ansell's share price is A$41.83. Ansell's Book Value per Sharefor the quarter that ended in Jun. 2026 was A$20.33. Hence, Ansell's P/B Ratio of today is 2.06.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Ansell Price-to-Tangible-Book Related Terms
Ansell Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Ansell's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ANN vs ISRG, BDX, RMD: Price-to-Tangible-Book Comparison
For the Medical Instruments & Supplies subindustry, Ansell's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ansell Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ansell's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Ansell's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Ansell (ASX:ANN) has a Price-to-Tangible-Book of 12.17 as of Sep. 08, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Ansell and its competitors. According to the industry distribution chart, Ansell ranks #624 out of 701 companies in the Medical Devices & Instruments industry, placing it in the top 89%.
Is Ansell's Price-to-Tangible-Book too high?
Ansell's current Price-to-Tangible-Book is 12.17. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.62. Ansell's value of 12.17 is 364.5% above this industry median. Based on the distribution chart, Ansell ranks #624 out of 701 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Ansell has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ansell's Price-to-Tangible-Book compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ansell ranks #624 out of 701 companies for Price-to-Tangible-Book. This places Ansell in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.62. Ansell's value of 12.17 is 364.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.62, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ansell's current Price-to-Tangible-Book of 12.17 is 364.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Ansell and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ansell's current Price-to-Tangible-Book is 12.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ansell stock overvalued right now?
Based on GuruFocus' analysis, Ansell (ASX:ANN) is currently considered Significantly Overvalued. The stock's GF Value™ is A$31.65, compared to a current price of A$41.83 — trading 32.2% above its estimated fair value. The current Price-to-Tangible-Book is 12.17 and 364.5% above the Medical Devices & Instruments industry median of 2.62. Ansell's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Ansell (ASX:ANN), the current Price-to-Tangible-Book is 12.17 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ansell (ASX:ANN) Overvalued in 2026?
Based on GuruFocus' analysis, Ansell stock appears to be overvalued.
The current stock price of A$41.83 is trading 32.2% above its estimated GF Value™ of A$31.65.
GuruFocus considers Ansell to be Significantly Overvalued.
Key valuation signals for ASX:ANN:
Price-to-Tangible-Book: 12.17
GF Value™: A$31.65 vs. price of A$41.83 (32.2% above fair value)
Industry Position: 364.5% above the Medical Devices & Instruments median (#624 of 701)
No single metric tells the full story. See the ASX:ANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ansell is a leading supplier of protective gloves for use in healthcare and industrial settings, earning approximately 55% of revenue and operating profit from the healthcare segment and the remainder from the industrial segment. The company holds a large number of patents, and the majority of sales come from its key branded product ranges. Ansell has a global manufacturing and distribution footprint and distributes via key partners as well as directly. Largest sales regions are North America and Europe, Middle East, and Africa. Asia-Pacific and Latin America, combined, are about one-fourth of sales.
74GF Score
Get the complete analysis for ASX:ANN
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ANN has been successfully added to your 
